Sareum Holdings PLC Sareum to Present at the LSX World Congress 2021
February 01 2021 - 1:00AM
RNS Non-Regulatory
TIDMSAR
Sareum Holdings PLC
01 February 2021
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sareum to Present at the LSX World Congress 2021
Cambridge, UK, 1 February 2021 - Sareum Holdings plc (AIM:SAR),
the specialist small molecule drug development business, announces
that its CEO, Dr Tim Mitchell, will give a Company presentation at
the 7(th) Annual LSX World Congress, which will be delivered
digitally between 1 and 5 February 2021.
The presentation will showcase Sareum's two proprietary
TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and SDC-1802,
targeting autoimmune diseases and cancers, respectively. Dr
Mitchell will also highlight the emerging potential of this
mechanism to modulate the severe inflammatory responses and
respiratory symptoms arising from Covid-19 and other viral
infections.
The presentation will be made through the conference website and
will be available to registered participants throughout the event -
www.lsxleaders.com/lsx-world-congress
A copy of the presentation will also be made available on
Sareum's website - www.sareum.com
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497 700
Strand Hanson Limited (Nominated
Adviser)
James Dance / James Bellman 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce / John Beresford-Peirse 020 3764 2341
Citigate Dewe Rogerson (Financial
PR)
Mark Swallow/ David Dible 020 7638 9571
About LSX World Congress
LSX World Congress gathers the founders and CEOs of innovative
start-ups through to publicly listed life sciences giants, and
everyone in between. It represents the breadth and depth of the
cutting-edge research and technology driving the advances in the
industry right now and in the near future.
The industry's c-suite will be joined by the sector's most
active investors, pharma and health tech BD&L teams, R&D
leaders, KOLs and top tier service companies who are moving the
sector forward.
About Sareum
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune diseases. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases,
including the 'cytokine storm' immune system overreaction to
Covid-19 and other viral infections, (SDC-1801) and cancer
immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary Phase 2 and comprehensive preclinical data suggest
SRA737 may have broad application in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra
continues to explore options that would enable the development of
SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at
www.sareum.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADZGZMVLVGMZM
(END) Dow Jones Newswires
February 01, 2021 02:00 ET (07:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2023 to Apr 2024